The Patent Finder

Method for Producing Recombinant Oncolytic Adenovirus with Modified E1A Cancer-Specific Promoter

Epicentrx, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application PCT/US2018/026977, filed Apr 10, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 12,291,726A549 Host Cells Comprising a Recombinant Oncolytic Adenovirus with Modified E1A Cancer-Specific Promoter
In force
 · High confidence
Epicentrx, Inc.In force
High confidence
US 11,999,973Method for Producing Recombinant Oncolytic Adenovirus with Modified E1A Cancer-Specific Promoter
In force
 · High confidence
Epicentrx, Inc.In force
High confidence
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited